nach oben

Current Hypertension Reports

Erschienen in:

01.06.2012 | CARDIOVASCULAR RISK AND HYPERTENSION (PW de LEEUW AND AH GRADMAN, SECTION EDITORS)

Vascular Calcification: Pathophysiology and Risk Factors

verfasst von: Neal X. Chen, Sharon M. Moe

Erschienen in: Current Hypertension Reports | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Vascular calcification can occur in nearly all arterial beds and in both the medial and intimal layers. The initiating factors and clinical consequences depend on the underlying disease state and location of the calcification. The best studied manifestation is coronary artery calcification, in part because of the obvious clinical consequences, but also because of CT-based imaging modalities. In the general population, the presence of coronary artery calcification increases cardiovascular risk above that predicted by traditional Framingham risk factors, suggesting the presence of nontraditional risk factors. In patients with chronic kidney disease (CKD), coronary artery calcification is more prevalent and markedly more severe than in the general population. In these CKD patients, nontraditional risk factors such as oxidative stress, advanced glycation end products, and disordered mineral metabolism are also more prevalent and more severe and offer mechanistic insight into the pathogenesis of vascular calcification.

Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2008;19(2):213–6.PubMedCrossRef

Ibanez B, Badimon JJ, Garcia MJ. Diagnosis of atherosclerosis by imaging. Am J Med. 2009;122(1 Suppl):S15–25.PubMedCrossRef

Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res. 2004;95(6):560–7.PubMedCrossRef

Proudfoot D, Shanahan CM, Weissberg PL. Vascular calcification: new insights into an old problem [editorial; comment]. J Pathol. 1998;185(1):1–3.PubMedCrossRef

Lehto S, Niskanen L, Suhonen M, Ronnemaa T, Laakso M. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 1996;16(8):978–83.PubMedCrossRef

London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18(9):1731–40.PubMedCrossRef

Moe SM, Chen NX. Calciphylaxis and vascular calcification: a continuum of extra-skeletal osteogenesis. Pediatr Nephrol. 2003;18:969–75.PubMedCrossRef

Raggi P, Gongora MC, Gopal A, Callister TQ, Budoff M, Shaw LJ. Coronary artery calcium to predict all-cause mortality in elderly men and women. J Am Coll Cardiol. 2008;52(1):17–23.PubMedCrossRef

Block, G.A., P. Raggi, A. Bellasi, L. Kooienga, and D.M. Spiegel, Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int, 2007.

10.

Mehrotra R, Budoff M, Hokanson JE, Ipp E, Takasu J, Adler S. Progression of coronary artery calcification in diabetics with and without chronic kidney disease. Kidney Int. 2005;68(3):1258–66.PubMedCrossRef

11.

Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68(4):1815–24.PubMedCrossRef

12.

Moe SM, O'Neill KD, Reslerova M, Fineberg N, Persohn S, Meyer CA. Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transplant. 2004;19(9):2387–93.PubMedCrossRef

13.

Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrology, Dialysis, Transplantation. 2000;15(2):218–23.PubMedCrossRef

14.

Gross ML, Meyer HP, Ziebart H, Rieger P, Wenzel U, Amann K, et al. Calcification of coronary intima and media: immunohistochemistry, backscatter imaging, and x-ray analysis in renal and nonrenal patients. Clin J Am Soc Nephrol. 2007;2(1):121–34.PubMedCrossRef

15.

Nakamura S, Ishibashi-Ueda H, Niizuma S, Yoshihara F, Horio T, Kawano Y. Coronary calcification in patients with chronic kidney disease and coronary artery disease. Clin J Am Soc Nephrol. 2009;4(12):1892–900.PubMedCrossRef

16.

Moe SM, O'Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int. 2002;61(2):638–47.PubMedCrossRef

17.

Allison MA, Hsi S, Wassel CL, Morgan C, Ix JH, Wright CM, et al. Calcified atherosclerosis in different vascular beds and the risk of mortality. Arterioscler Thromb Vasc Biol. 2012;32(1):140–6.PubMedCrossRef

18.

Chen NX, O'Neill KD, Chen X, Moe SM. Annexin-mediated matrix vesicle calcification in vascular smooth muscle cells. J Bone Miner Res. 2008;23(11):1798–805.PubMedCrossRef

19.

Shroff RC, McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation. 2008;118(17):1748–57.PubMedCrossRef

20.

•• Chen, N.X., F. Kircelli, K.D. O'Neill, X. Chen, and S.M. Moe, Verapamil inhibits calcification and matrix vesicle activity of bovine vascular smooth muscle cells. Kidney Int, 2010. 77(5): p. 436-42. This study provides evidence of the importance of extracellular calcium in MV activity and calcification.PubMedCrossRef

21.

Barreto DV, Barreto Fde C, Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, et al. Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study. Am J Kidney Dis. 2008;52(6):1139–50.PubMedCrossRef

22.

Ketteler M, Biggar PH. Review article: getting the balance right: assessing causes and extent of vascular calcification in chronic kidney disease. Nephrology (Carlton). 2009;14(4):389–94.CrossRef

23.

Everhart JE, Pettitt DJ, Knowler WC, Rose FA, Bennett PH. Medial arterial calcification and its association with mortality and complications of diabetes. Diabetologia. 1988;31(1):16–23.PubMed

24.

Mehrotra R, Budoff M, Christenson P, Ipp E, Takasu J, Gupta A, et al. Determinants of coronary artery calcification in diabetics with and without nephropathy. Kidney Int. 2004;66(5):2022–31.PubMedCrossRef

25.

Chertow, G.M., P. Raggi, S. Chasan-Taber, J. Bommer, H. Holzer, and S.K. Burke, Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant, 2004.

26.

Orakzai SH, Nasir K, Blaha M, Blumenthal RS, Raggi P. Non-HDL cholesterol is strongly associated with coronary artery calcification in asymptomatic individuals. Atherosclerosis. 2009;202(1):289–95.PubMedCrossRef

27.

Henein MY, Owen A. Statins moderate coronary stenoses but not coronary calcification: results from meta-analyses. Int J Cardiol. 2011;153(1):31–5.PubMedCrossRef

28.

Raggi P, Cooil B, Callister TQ. Use of electron beam tomography data to develop models for prediction of hard coronary events. Am Heart J. 2001;141(3):375–82.PubMedCrossRef

29.

Budoff MJ, Rader DJ, Reilly MP, Mohler 3rd ER, Lash J, Yang W, et al. Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis. 2011;58(4):519–26.PubMedCrossRef

30.

Detrano R. The ethnic-specific nature of mechanisms for coronary heart disease. J Am Coll Cardiol. 2003;41(1):45–6.PubMedCrossRef

31.

Elias-Smale SE, Proenca RV, Koller MT, Kavousi M, van Rooij FJ, Hunink MG, et al. Coronary calcium score improves classification of coronary heart disease risk in the elderly: the Rotterdam study. J Am Coll Cardiol. 2010;56(17):1407–14.PubMedCrossRef

32.

Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291(2):210–5.PubMedCrossRef

33.

Kalsch H, Lehmann N, Mohlenkamp S, Neumann T, Slomiany U, Schmermund A, et al. Association of coronary artery calcium and congestive heart failure in the general population: results of the Heinz Nixdorf Recall study. Clin Res Cardiol. 2010;99(3):175–82.PubMedCrossRef

34.

•• Peters, S.A., M. Bakker, H.M. den Ruijter, and M.L. Bots, Added value of CAC in risk stratification for cardiovascular events: a systematic review. Eur J Clin Invest, 2012. 42(1): p. 110-6. This systemic review provides important information regarding the risk factors for coronary artery calcification.PubMedCrossRef

35.

•• Savoia, C., D. Burger, N. Nishigaki, A. Montezano, and R.M. Touyz, Angiotensin II and the vascular phenotype in hypertension. Expert Rev Mol Med, 2011. 13: p. e11. This review describes the roles of renin-angiotensin systems in VSMC growth, apoptosis, differentiation, and calcification.

36.

• Armstrong, Z.B., D.R. Boughner, M. Drangova, and K.A. Rogers, Angiotensin II type 1 receptor blocker inhibits arterial calcification in a pre-clinical model. Cardiovasc Res, 2011. 90(1): p. 165-70. This article provides evidence regarding the angiotensin receptor in the development of arterial calcification.PubMedCrossRef

37.

Tokumoto M, Mizobuchi M, Finch JL, Nakamura H, Martin DR, Slatopolsky E. Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: sevelamer carbonate prevents vascular calcification. Am J Nephrol. 2009;29(6):582–91.PubMedCrossRef

38.

Wu SY, Yu YR, Cai Y, Jia LX, Wang X, Xiao CS, et al. Endogenous aldosterone is involved in vascular calcification in rat. Exp Biol Med (Maywood). 2012;237(1):31–7.CrossRef

39.

Chen NX, Duan D, O'Neill D. K, and S.M. Moe, High glucose increases the expression of Cbfa1 and BMP-2 and enhances the calcification of vascular smooth muscle cells. Nephrol Dial Transplant. 2006;21(12):3435–42.PubMedCrossRef

40.

Al-Aly Z, Shao JS, Lai CF, Huang E, Cai J, Behrmann A, et al. Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/- mice. Arterioscler Thromb Vasc Biol. 2007;27(12):2589–96.PubMedCrossRef

41.

Bostrom KI, Jumabay M, Matveyenko A, Nicholas SB, Yao Y. Activation of vascular bone morphogenetic protein signaling in diabetes mellitus. Circ Res. 2011;108(4):446–57.PubMedCrossRef

42.

Parhami F, Basseri B, Hwang J, Tintut Y, Demer LL. High-density lipoprotein regulates calcification of vascular cells. Circ Res. 2002;91(7):570–6.PubMedCrossRef

43.

• Ting, T.C., S. Miyazaki-Anzai, M. Masuda, M. Levi, L.L. Demer, Y. Tintut, and M. Miyazaki, Increased lipogenesis and stearate accelerate vascular calcification in calcifying vascular cells. J Biol Chem, 2011. 286(27): p. 23938-49. This article provides evidence for lipid metabolism and lipogenesis as risk factors for vascular calcification.PubMedCrossRef

44.

Abedin M, Lim J, Tang TB, Park D, Demer LL, Tintut Y. N-3 fatty acids inhibit vascular calcification via the p38-mitogen-activated protein kinase and peroxisome proliferator-activated receptor-gamma pathways. Circ Res. 2006;98(6):727–9.PubMedCrossRef

45.

Parhami F, Morrow AD, Balucan J, Leitinger N, Watson AD, Tintut Y. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol. 1997;17(4):680–7.PubMedCrossRef

46.

Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107(3):363–9.PubMedCrossRef

47.

Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, et al. Immunologic function and survival in hemodialysis patients. Kidney Int. 1998;54(1):236–44.PubMedCrossRef

48.

Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation. 2002;106(1):100–5.PubMedCrossRef

49.

Stompor T, Krasniak A, Sulowicz W, Dembinska-Kiec A, Janda K, Wojcik K, et al. Changes in common carotid artery intima-media thickness over 1 year in patients on peritoneal dialysis. Nephrol Dial Transplant. 2005;20(2):404–12.PubMedCrossRef

50.

Aikawa E, Nahrendorf M, Figueiredo JL, Swirski FK, Shtatland T, Kohler RH, et al. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation. 2007;116(24):2841–50.PubMedCrossRef

51.

Tintut Y, Patel J, Parhami F, Demer LL. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation. 2000;102(21):2636–42.PubMed

52.

Tintut Y, Patel J, Territo M, Saini T, Parhami F, Demer LL. Monocyte/macrophage regulation of vascular calcification in vitro. Circulation. 2002;105(5):650–5.PubMedCrossRef

53.

Okazaki H, Shioi A, Hirowatari K, Koyama H, Fukumoto S, Ishimura E, et al. Phosphatidylinositol 3-kinase/Akt pathway regulates inflammatory mediators-induced calcification of human vascular smooth muscle cells. Osaka City Med J. 2009;55(2):71–80.PubMed

54.

Amore A, Coppo R. Immunological basis of inflammation in dialysis. Nephrol Dial Transplant. 2002;17 Suppl 8:16–24.PubMedCrossRef

55.

Zoccali C, Mallamaci F, Tripepi G. Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol. 2004;15 Suppl 1:S77–80.PubMedCrossRef

56.

• Yamada, S., M. Taniguchi, M. Tokumoto, J. Toyonaga, K. Fujisaki, T. Suehiro, H. Noguchi, M. Iida, K. Tsuruya, and T. Kitazono, The antioxidant tempol ameliorates arterial medial calcification in uremic rats: Important role of oxidative stress in the pathogenesis of vascular calcification in chronic kidney disease. J Bone Miner Res, 2011. This study demonstrated that oxidative stress induced by uremia may play a role in the development of vascular calcification in CKD.

57.

Sutra T, Morena M, Bargnoux AS, Caporiccio B, Canaud B, Cristol JP. Superoxide production: a procalcifying cell signalling event in osteoblastic differentiation of vascular smooth muscle cells exposed to calcification media. Free Radic Res. 2008;42(9):789–97.PubMedCrossRef

58.

Liberman M, Bassi E, Martinatti MK, Lario FC, Wosniak Jr J, Pomerantzeff PM, et al. Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification. Arterioscler Thromb Vasc Biol. 2008;28(3):463–70.PubMedCrossRef

59.

You H, Yang H, Zhu Q, Li M, Xue J, Gu Y, et al. Advanced oxidation protein products induce vascular calcification by promoting osteoblastic trans-differentiation of smooth muscle cells via oxidative stress and ERK pathway. Ren Fail. 2009;31(4):313–9.PubMedCrossRef

60.

Byon CH, Javed A, Dai Q, Kappes JC, Clemens TL, Darley-Usmar VM, et al. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J Biol Chem. 2008;283(22):15319–27.PubMedCrossRef

61.

Tintut Y, Parhami F, Tsingotjidou A, Tetradis S, Territo M, Demer LL. 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway. J Biol Chem. 2002;277(16):14221–6.PubMedCrossRef

62.

Tseng W, Lu J, Bishop GA, Watson AD, Sage AP, Demer L, et al. Regulation of interleukin-6 expression in osteoblasts by oxidized phospholipids. J Lipid Res. 2010;51(5):1010–6.PubMedCrossRef

63.

Demer LL. Vascular calcification and osteoporosis: inflammatory responses to oxidized lipids. Int J Epidemiol. 2002;31(4):737–41.PubMedCrossRef

64.

Niwa T, Katsuzaki T, Miyazaki S, Miyazaki T, Ishizaki Y, Hayase F, et al. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest. 1997;99(6):1272–80.PubMedCrossRef

65.

Miyata T, Sprague SM. Advanced glycation of beta 2-microglobulin in the pathogenesis of bone lesions in dialysis-associated amyloidosis. Nephrol, Dial, Transplant. 1996;11 Suppl 3:86–90.CrossRef

66.

Sakata N, Noma A, Yamamoto Y, Okamoto K, Meng J, Takebayashi S, et al. Modification of elastin by pentosidine is associated with the calcification of aortic media in patients with end-stage renal disease. Nephrol Dial Transplant. 2003;18(8):1601–9.PubMedCrossRef

67.

Yamagishi S, Fujimori H, Yonekura H, Tanaka N, Yamamoto H. Advanced glycation endproducts accelerate calcification in microvascular pericytes. Biochem Biophys Res Commun. 1999;258(2):353–7.PubMedCrossRef

68.

Tanikawa T, Okada Y, Tanikawa R, Tanaka Y. Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res. 2009;46(6):572–80.PubMedCrossRef

69.

Naka Y, Bucciarelli LG, Wendt T, Lee LK, Rong LL, Ramasamy R, et al. RAGE axis: Animal models and novel insights into the vascular complications of diabetes. Arterioscler Thromb Vasc Biol. 2004;24(8):1342–9.PubMedCrossRef

70.

Ren X, Shao H, Wei Q, Sun Z, Liu N. Advanced glycation end-products enhance calcification in vascular smooth muscle cells. J Int Med Res. 2009;37(3):847–54.PubMed

71.

Suga T, Iso T, Shimizu T, Tanaka T, Yamagishi S, Takeuchi M, et al. Activation of receptor for advanced glycation end products induces osteogenic differentiation of vascular smooth muscle cells. J Atheroscler Thromb. 2011;18(8):670–83.PubMedCrossRef

72.

Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607–17.PubMedCrossRef

73.

Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342(20):1478–83.PubMedCrossRef

74.

Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62(1):245–52.PubMedCrossRef

75.

Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005;112(17):2627–33.PubMedCrossRef

76.

Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87(7):E10–7.PubMed

77.

Jono S, Peinado C, Giachelli CM. Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem. 2000;275(26):20197–203.PubMedCrossRef

78.

Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res. 2001;89(12):1147–54.PubMedCrossRef

79.

Werner A, Dehmelt L, Nalbant P. Na +-dependent phosphate cotransporters: the NaPi protein families. J Exp Biol. 1998;201(Pt 23):3135–42.PubMed

80.

Li X, Yang HY, Giachelli CM. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res. 2006;98(7):905–12.PubMedCrossRef

81.

Chen NX, O'Neill KD, Duan D, Moe SM. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int. 2002;62(5):1724–31.PubMedCrossRef

82.

Chen, N.X., D. Duan, D. O'Neill K, G.O. Wolisi, J.J. Koczman, R. Laclair, and S.M. Moe, The mechanisms of uremic serum-induced expression of bone matrix proteins in bovine vascular smooth muscle cells. Kidney Int, 2006.

83.

Hosaka N, Mizobuchi M, Ogata H, Kumata C, Kondo F, Koiwa F, et al. Elastin degradation accelerates phosphate-induced mineralization of vascular smooth muscle cells. Calcif Tissue Int. 2009;85(6):523–9.PubMedCrossRef

84.

Simionescu A, Philips K, Vyavahare N. Elastin-derived peptides and TGF-beta1 induce osteogenic responses in smooth muscle cells. Biochem Biophys Res Commun. 2005;334(2):524–32.PubMedCrossRef

85.

Lee KS, Kim HJ, Li QL, Chi XZ, Ueta C, Komori T, et al. Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol. 2000;20(23):8783–92.PubMedCrossRef

86.

Bouvet C, Moreau S, Blanchette J, de Blois D, Moreau P. Sequential activation of matrix metalloproteinase 9 and transforming growth factor beta in arterial elastocalcinosis. Arterioscler Thromb Vasc Biol. 2008;28(5):856–62.PubMedCrossRef

87.

• Chen, N.X., Kalisha D. O’Neill, Xianming Chen Kiattisunthorn, Kraiwporn, Vincent H. Gattone and Sharon M. Moe, Activation of arterial matrix metalloproteinases leads to vascular calcification in chronic kidney disease. American Journal of Nephrology, 2011. Vol. 34(No. 3). This study suggests that matrix degradation plays an important role in vascular calcification in CKD.

88.

Moe SM, Chertow GM. The Case against Calcium-Based Phosphate Binders. Clin J Am Soc Nephrol. 2006;1(4):697–703.PubMedCrossRef

89.

Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int. 2004;66(6):2293–9.PubMedCrossRef

90.

Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004;15(11):2857–67.PubMedCrossRef

91.

Lomashvili KA, Cobbs S, Hennigar RA, Hardcastle KI, O'Neill WC. Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. J Am Soc Nephrol. 2004;15(6):1392–401.PubMedCrossRef

92.

• Shroff, R.C., R. McNair, J.N. Skepper, N. Figg, L.J. Schurgers, J. Deanfield, L. Rees, and C.M. Shanahan, Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol, 2010. 21(1): p. 103-12. This study demonstrates an important role for calcium in VSMC calcification. PubMedCrossRef

93.

Kapustin AN, Davies JD, Reynolds JL, McNair R, Jones GT, Sidibe A, et al. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ Res. 2011;109(1):e1–e12.PubMedCrossRef

94.

Wolf M. Fibroblast growth factor 23 and the future of phosphorus management. Curr Opin Nephrol Hypertens. 2009;18(6):463–8.PubMedCrossRef

95.

Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390(6655):45–51.PubMedCrossRef

96.

Balci M, Kirkpantur A, Gulbay M, Gurbuz OA. Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients. Hemodial Int. 2010;14(4):425–32.PubMedCrossRef

97.

•Desjardins, L., S. Liabeuf, C. Renard, A. Lenglet, H.D. Lemke, G. Choukroun, T.B. Drueke, and Z.A. Massy, FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int, 2011. This study demonstrates an important role for FGF23 in vascular calcification in CKD.

98.

Stubbs J, Liu S, Quarles LD. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial. 2007;20(4):302–8.PubMedCrossRef

99.

El-Abbadi MM, Pai AS, Leaf EM, Yang HY, Bartley BA, Quan KK, et al. Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int. 2009;75(12):1297–307.PubMedCrossRef

100.

Takei, Y., H. Yamamoto, T. Sato, A. Otani, M. Kozai, M. Masuda, Y. Taketani, K. Muto-Sato, B. Lanske, and E. Takeda, Stanniocalcin 2 is associated with ectopic calcification in alpha-klotho mutant mice and inhibits hyperphosphatemia-induced calcification in aortic vascular smooth muscle cells. Bone, 2012.

Titel: Vascular Calcification: Pathophysiology and Risk Factors
verfasst von: Neal X. Chen
Sharon M. Moe
Publikationsdatum: 01.06.2012
Verlag: Current Science Inc.
Erschienen in: Current Hypertension Reports / Ausgabe 3/2012
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-012-0265-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

The Role of Angiotensin II Receptors in Stroke Protection

Angiotensin Receptor Blockers and Tumorigenesis: Something To Be (or Not To Be) Concerned About?

Renal Denervation in Human Hypertension: Mechanisms, Current Findings, and Future Prospects

Hypertension in Postmenopausal Women

Carotid Baroreceptor Activation for the Treatment of Resistant Hypertension and Heart Failure